AIMS: Abnormal bone metabolism and progressive demineralization have been described in patients with heart failure (HF). We hypothesized that mechanical unloading through implantation of a ventricular assist device (VAD) with subsequent haemodynamic improvement would correct abnormal bone metabolism in patients with advanced HF. METHODS AND RESULTS: Serum was collected from 14 controls, 20 patients with moderate HF, 34 patients with advanced HF undergoing VAD implantation, and 34 patients at the time of VAD explantation (mean duration: 169 ± 125 days). Bone metabolism markers were measured using enzyme-linked immunosorption assay (ELISA) or chemiluminescence immunoassay (CLIA). Compared with controls, HF patients showed increased parathyroid hormone (PTH: 42 ± 19 vs. 117 ± 117 pg/mL in HF; P < 0.02) with decreased 25-hydroxyvitamin D [25(OH)D: 29 ± 14 vs. 21 ± 11 ng/mL in HF; P = 0.05]. While procollagen-1 N-terminal peptide (P1NP) and osteocalcin were similar, cross-linked C- and N-telopeptides of type I collagen (CTX and NTX) were both higher in HF (NTX: 14 ± 6 vs. 20 ± 11 ng/mL; P < 0.05; CTX: 0.35 ± 0.13 vs. 1.05 ± 0.78 ng/mL; P < 0.01 for controls and HF, respectively). P1NP increased markedly after VAD implantation (49 ± 37 vs. 121 ± 62 ng/mL; P < 0.0001), with a mild decrease in CTX and NTX levels indicating a shift towards anabolic bone formation. Serum PTH correlated with estimated glomerular filtration rate (r = -0.245, P < 0.05). CONCLUSION: Patients with advanced HF are characterized by increased levels of biochemical markers of bone resorption potentially as a result of secondary hyperparathyroidism and uncoupling of bone remodelling. Haemodynamic improvement and mechanical unloading after VAD implantation lead to correction of bone metabolism and increased levels of anabolic bone formation markers.
AIMS: Abnormal bone metabolism and progressive demineralization have been described in patients with heart failure (HF). We hypothesized that mechanical unloading through implantation of a ventricular assist device (VAD) with subsequent haemodynamic improvement would correct abnormal bone metabolism in patients with advanced HF. METHODS AND RESULTS: Serum was collected from 14 controls, 20 patients with moderate HF, 34 patients with advanced HF undergoing VAD implantation, and 34 patients at the time of VAD explantation (mean duration: 169 ± 125 days). Bone metabolism markers were measured using enzyme-linked immunosorption assay (ELISA) or chemiluminescence immunoassay (CLIA). Compared with controls, HF patients showed increased parathyroid hormone (PTH: 42 ± 19 vs. 117 ± 117 pg/mL in HF; P < 0.02) with decreased 25-hydroxyvitamin D [25(OH)D: 29 ± 14 vs. 21 ± 11 ng/mL in HF; P = 0.05]. While procollagen-1 N-terminal peptide (P1NP) and osteocalcin were similar, cross-linked C- and N-telopeptides of type I collagen (CTX and NTX) were both higher in HF (NTX: 14 ± 6 vs. 20 ± 11 ng/mL; P < 0.05; CTX: 0.35 ± 0.13 vs. 1.05 ± 0.78 ng/mL; P < 0.01 for controls and HF, respectively). P1NP increased markedly after VAD implantation (49 ± 37 vs. 121 ± 62 ng/mL; P < 0.0001), with a mild decrease in CTX and NTX levels indicating a shift towards anabolic bone formation. Serum PTH correlated with estimated glomerular filtration rate (r = -0.245, P < 0.05). CONCLUSION:Patients with advanced HF are characterized by increased levels of biochemical markers of bone resorption potentially as a result of secondary hyperparathyroidism and uncoupling of bone remodelling. Haemodynamic improvement and mechanical unloading after VAD implantation lead to correction of bone metabolism and increased levels of anabolic bone formation markers.
Authors: Rami N Khouzam; Dwight A Dishmon; Victor Farah; Sherri D Flax; Laura D Carbone; Karl T Weber Journal: Am J Med Sci Date: 2006-01 Impact factor: 2.378
Authors: Stuart D Russell; Joseph G Rogers; Carmelo A Milano; David B Dyke; Francis D Pagani; Juan M Aranda; Charles T Klodell; Andrew J Boyle; Ranjit John; Leway Chen; H Todd Massey; David J Farrar; John V Conte Journal: Circulation Date: 2009-11-23 Impact factor: 29.690
Authors: Ewa A Jankowska; Justyna Jakubaszko; Aldona Cwynar; Jacek Majda; Beata Ponikowska; Dorota Kustrzycka-Kratochwil; Krzysztof Reczuch; Ludmila Borodulin-Nadzieja; Waldemar Banasiak; Philip A Poole-Wilson; Piotr Ponikowski Journal: Eur J Heart Fail Date: 2009-01 Impact factor: 15.534
Authors: N Emaus; C G Gjesdal; B Almås; M Christensen; A S Grimsgaard; G K R Berntsen; L Salomonsen; V Fønnebø Journal: Osteoporos Int Date: 2009-11-25 Impact factor: 4.507
Authors: Nicolas Verheyen; Astrid Fahrleitner-Pammer; Evgeny Belyavskiy; Martin R Gruebler; Hans Peter Dimai; Karin Amrein; Klemens Ablasser; Johann Martensen; Cristiana Catena; Elisabeth Pieske-Kraigher; Caterina Colantonio; Jakob Voelkl; Florian Lang; Ioana Alesutan; Andreas Meinitzer; Winfried März; Helmut Brussee; Burkert Pieske; Stefan Pilz; Andreas Tomaschitz Journal: PLoS One Date: 2017-04-13 Impact factor: 3.240
Authors: Ulrike Schulze-Späte; Iman Mizani; Kristina Rodriguez Salaverry; Jaime Chang; Christina Wu; Meaghan Jones; Peter J Kennel; Danielle L Brunjes; Tse-Hwei Choo; Tomoko S Kato; Donna Mancini; John Grbic; P Christian Schulze Journal: ESC Heart Fail Date: 2017-03-01
Authors: Damien Gruson; Benjamin Ferracin; Sylvie A Ahn; Claudia Zierold; Frank Blocki; Douglas M Hawkins; Fabrizio Bonelli; Michel F Rousseau Journal: PLoS One Date: 2015-08-26 Impact factor: 3.240